newsfilter
← Latest News
GlobeNewswire·

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary